Close Menu

PD-L1 Biomarkers

News and reporting on PD-L1 biomarkers.

Pembrolizumab provided long-term overall survival benefit in second-line treatment and can be effectively used for retreatment after disease progression.

The study of cancer immunity biomarkers revealed complex immune profiles for most tumors, suggesting the need for customized combinations of immunotherapies.

The approval is based on a Phase III trial showing that Tecentriq significantly improved survival in patients with metastatic non-small cell lung cancer.

This is the first anti-PD-1 drug approved for front-line treatment of advanced and unresectable, recurrent head and neck cancer in the EU.

The results are of interest to drugmakers looking for scalable technology solutions for assessment of PD-L1 for predicting immunotherapy response.

Promega's microsatellite instability technology will be used to develop an on-label, solid tumor companion diagnostic for pembrolizumab.

A new study suggests that using rotavirus in combination with immune checkpoint blockade therapy could give oncologists a new way to treat pediatric cancers.

The European Commission will review CHMP's recommendation and is slated to issue a final decision regarding marketing authorization later this year.

In KEYNOTE-522, early-stage TNBC patients on the immunotherapy and chemotherapy combination benefitted regardless of their PD-L1 expression status.  

The assay was developed in partnership with Merck and is intended as a companion diagnostic for that firm's anti-PD-L1 immunotherapy.

Pages